eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2020-09-25 13 3 1381 1386 10.13005/bpj/2007 34705 article Syeda Ayesha Siddiqua 1 Md. Zubair Ahmed 2 Abdullah Ansari 3 Department of Pharmacology, Shadan Institute of Medical Sciences, Teaching Hospital and Research Centre, Hyderabad – 500008, Telangana, India 2Department of Pharmacology, Mamata Academy of Medical Sciences, Bachupally, Hyderabad – 500090, Telangana, India Department of Pharmacology, Ayaan Institute of Medical Sciences, Teaching Hospital and Research Centre, Hyderabad- 501504, Telangana, India Background: Urticaria has a wide spectrum of clinical presentations and causes. Patients with urticaria make up a large proportion of referrals to allergy clinics. Urticaria is characterized by wheals with swelling which can appear on any body part. This study is attempted to match the efficiency and safety of olopatadine with rupatadine in the treatment of chronic urticaria of idiopathic origin. Methods: Based on the inclusion and exclusion criteria, sixty patients of urticaria were divided into two treatment groups, olopatadine, and rupatadine groups. The groups received olopatadine and rupatadine, orally with doses of 10mg/day respectively, for 8weeks. Clinical improvement was evaluated through parameters in terms of change in Absolute Eosinophil Count (AEC), serum IgE level, Total Symptom Score (TSS), and safety was considered on the adverse events reported. Results: AEC was considerably depressed by both drugs but the olopatadine group was superior in its action. Within the olopatadine group, a greater decline in the serum IgE level is observed than that of the rupatadine group. Olopatadine was found to be better in the reduction of TSS. The prevalence of adverse effects (gastric irritation, drowsiness, headache, and dryness of mouth) was less in the olopatadine group when compared to the rupatadine group. Conclusions: From the analysis of results, the study shows that olopatadine is a better choice in the treatment of chronic urticaria of idiopathic origin in comparison to rupatadine as a result of its better efficiency and safety profile. https://biomedpharmajournal.org/vol13no3/the-efficiency-and-safety-of-olopatadine-against-rupatadine-in-chronic-urticaria-of-idiopathic-origin-a-comparative-study/ Absolute Eosinophil Count Chronic Urticaria of Idiopathic Origin Olopatadine Rupatadine Serum IgE Total Symptom Score